Template:Pyelonephritis antibiotics: Difference between revisions

No edit summary
No edit summary
 
(12 intermediate revisions by 6 users not shown)
Line 1: Line 1:
===Outpatient===
''Treatment is targeted at [[E. coli]], [[Enterococcus]], [[Klebsiella]], [[Proteus mirabilis]], [[S. saprophyticus]].''
;Frequently, first dose is given IV before outpatient treatment ([[ceftriaxone]] or [[gentamycin]]
====Outpatient====
#[[Ciprofloxacin]] 500mg BID x10-14d OR
''Consider one dose of [[Ceftriaxone]] 1g IV or [[Gentamycin]] 7mg/kg IV if the regional susceptibility of [[TMP/SMX]] or [[Fluoroquinolones]] is <80%''
#[[Cefpodoxime]] 200 mg BID x10-14d
*[[Ciprofloxacin]] 500mg PO BID x7 days '''OR'''
*[[Trimethoprim-Sulfamethoxazole DS]] 160/800mg PO BID x14 days '''OR'''<ref>Gupta K, Hooton TM, Naber KG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women. Clinical Infectious Diseases. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257</ref>
*[[Cephalexin]] 500mg QID PO x 10-14 days (OR consider 1000mg BID if difficulty with QID regimen) '''OR'''
*[[Cefdinir]] 300mg BID PO x 10-14 days '''OR'''
*[[Cefpodoxime]] 200mg PO BID x 10 days '''OR'''<ref>Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.</ref>
*[[Cefixime]] 400mg PO daily x 10 days '''OR'''<ref>Acute Pyelonephritis in Adults.  Johnson, JR and Russo, TA.  New England Journal of Medicine 2018; 378:48-59.</ref>
*[[Levofloxacin]] 750mg PO QD x7 days<ref>Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.</ref>


===Inpatient Options===
====Adult Inpatient Options====
*[[Ciprofloxacin]] 400mg IV q12hr OR
*[[Ciprofloxacin]] 400mg IV q12hr '''OR'''
*[[Ceftriaxone]] 1gm IV QD OR
*[[Ceftriaxone]] 1gm IV QD <span style="color:red">'''(Preferred in pregnancy)'''</span> '''OR'''
*Cefotaxime 1-2gm IV q8hr OR
*Cefotaxime 1-2gm IV q8hr '''OR'''
*[[Gentamicin]] 3mg/kg/day divided q8hr +/- ampicillin 1–2 gm q4hr OR
*[[Gentamicin]] 3mg/kg/day divided q8hr +/- [[ampicillin]] 1–2 gm q4hr '''OR'''
*[[Piperacillin/Tazobactam]] 3.375 gm IV q6hr OR
*[[Piperacillin/Tazobactam]] 3.375 gm IV q6hr '''OR'''
*[[Cefepime]] 2gm IV q8hr OR
*[[Cefepime]] 2gm IV q8hr '''OR'''
*[[Imipenem]] 500mg IV q8hr
*[[Imipenem]] 500mg IV q8hr
====Pediatric Inpatient Options====
*[[Ceftriaxone]] 75mg/kg IV QD '''OR'''
*[[Cefotaxime]] 50mg/kg IV q8hrs '''OR'''
*[[Ampicillin]] 25mg/kg IV q6hrs '''+''' [[Gentamicin]] 2.5mg/kg IV q8hrs

Latest revision as of 22:37, 21 September 2022

Treatment is targeted at E. coli, Enterococcus, Klebsiella, Proteus mirabilis, S. saprophyticus.

Outpatient

Consider one dose of Ceftriaxone 1g IV or Gentamycin 7mg/kg IV if the regional susceptibility of TMP/SMX or Fluoroquinolones is <80%

Adult Inpatient Options

Pediatric Inpatient Options

  1. Gupta K, Hooton TM, Naber KG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women. Clinical Infectious Diseases. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257
  2. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.
  3. Acute Pyelonephritis in Adults. Johnson, JR and Russo, TA. New England Journal of Medicine 2018; 378:48-59.
  4. Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.